For patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
When administering KEYTRUDA and LENVIMA in combination for the treatment of endometrial carcinoma, interrupt one or both drugs or dose reduce LENVIMA as appropriate.
200 mg IV infusion
over 30 minutes
every 3 weeks
IV = intravenous.
20 mg orally once daily at the same time each day
Taken with or without food
Swallowed whole or dissolved in a glass of liquid
Learn about LENVIMA $0 Co-Pay and Specialty Pharmacies
Capsules may not be shown at actual size.
Selected Safety Information for
KEYTRUDA® (pembrolizumab)
PD-1 = programmed death receptor-1; PD-L1 = programmed death ligand 1
Before prescribing KEYTRUDA® (pembrolizumab), please read the accompanying Prescribing Information. The Medication Guide also is available.
Selected Safety Information for
LENVIMA® (lenvatinib)
Adverse reactions led to dose reduction or interruption in 88% of patients receiving LENVIMA. The most common adverse reactions (≥5%) resulting in dose reduction or interruption of LENVIMA were fatigue (32%), hypertension (26%), diarrhea (18%), nausea (13%), palmar-plantar erythrodysesthesia (13%), vomiting (13%), decreased appetite (12%), musculoskeletal pain (11%), stomatitis (9%), abdominal pain (7%), hemorrhages (7%), renal impairment (6%), decreased weight (6%), rash (5%), headache (5%), increased lipase (5%), and proteinuria (5%).
Fatal adverse reactions occurred in 3% of patients receiving LENVIMA + KEYTRUDA, including gastrointestinal perforation, RPLS with intraventricular hemorrhage, and intracranial hemorrhage.
Serious adverse reactions occurred in 52% of patients receiving LENVIMA + KEYTRUDA. Serious adverse reactions in ≥3% of patients were hypertension (9%), abdominal pain (6%), musculoskeletal pain (5%), hemorrhage (4%), fatigue (4%), nausea (4%), confusional state (4%), pleural effusion (4%), adrenal insufficiency (3%), colitis (3%), dyspnea (3%), and pyrexia (3%).
Permanent discontinuation due to adverse reaction (grade 1-4) occurred in 21% of patients who received LENVIMA + KEYTRUDA. The most common adverse reactions (>2%) resulting in discontinuation of LENVIMA were gastrointestinal perforation or fistula (2%), muscular weakness (2%), and pancreatitis (2%).
QTc = corrected QT interval; MRI = magnetic resonance imaging; CNS = central nervous system.
Before prescribing LENVIMA® (lenvatinib), please read the accompanying Prescribing Information and Patient Information.